Key facts
- Orbis Diagnostics’s last known valuation is $10.9M (Dec 2022).
- It has raised $2.3M; the latest was Later Stage VC ($350K) in Jul 2025.
- Notable investors include Aspire NZ Seed Fund, Auckland UniServices, Booster Innovation Fund, Clare Ventures, Harvey Investment Fund — 9 tracked in total.
- Status: Privately Held (backing).
- ·The complete investor list — 9 names
- ·Watchlist + deal alerts for Orbis Diagnostics
- ·The full record, as it builds
Funding rounds
No funding rounds for Orbis Diagnostics are on record yet — either the company hasn't raised institutional capital, or the raise hasn't surfaced in our sources.
About Orbis Diagnostics
Developer of a healthcare technology intended for point-of-care diagnostics. The company's automated technology reports results within minutes for up to eight tests from a single sample or a single test type for people, to support time-critical health management decisions, enabling individuals within society to make life-changing decisions with confidence.
- Sector
- Healthcare
- HQ
- Auckland, New Zealand
- Founded
- 2016
- Employees
- 19
- Website
- orbisdiagnostics.com/
- Ownership
- Privately Held (backing)
Orbis Diagnostics doesn't have a composite mark yet — a PA Mark is published once enough pricing inputs exist (trade prints, fund marks, round prices). The rest of the record below builds toward it.
Recorded secondary trades
No secondary trades in Orbis Diagnostics shares have been recorded yet. When a print lands — third-party, direct report, or platform — it appears here with structure, source, and price.
Institutional fund marks
No SEC-registered fund has reported a fair-value mark on Orbis Diagnostics in its N-PORT filings yet. We sweep new filings monthly.